

DARZALEX FDA APPROVAL HISTORY

DARZALEX FDA APPROVAL HISTORY HAS BEEN A SIGNIFICANT JOURNEY IN THE REALM OF ONCOLOGY, PARTICULARLY FOR THE TREATMENT OF MULTIPLE MYELOMA. DEVELOPED BY JANSSEN BIOTECH, DARZALEX (DARATUMUMAB) IS A MONOCLONAL ANTIBODY THAT HAS TRANSFORMED THE LANDSCAPE OF HOW MULTIPLE MYELOMA IS TREATED. THIS ARTICLE WILL EXPLORE THE FDA APPROVAL HISTORY OF DARZALEX, DETAILING ITS INITIAL APPROVAL, SUBSEQUENT INDICATIONS, AND THE IMPACT IT HAS HAD ON PATIENT CARE.

UNDERSTANDING DARZALEX AND ITS MECHANISM OF ACTION

DARZALEX IS A HUMAN IgG1k MONOCLONAL ANTIBODY THAT TARGETS CD38, A PROTEIN THAT IS HIGHLY EXPRESSED ON THE SURFACE OF MULTIPLE MYELOMA CELLS. BY BINDING TO CD38, DARZALEX TRIGGERS SEVERAL MECHANISMS THAT LEAD TO THE DESTRUCTION OF THESE MALIGNANT CELLS, INCLUDING:

- APOPTOSIS: INDUCING PROGRAMMED CELL DEATH IN MYELOMA CELLS.
- IMMUNE-MEDIATED CELL LYSIS: ACTIVATING THE IMMUNE SYSTEM TO ATTACK AND KILL CANCER CELLS.
- INHIBITION OF TUMOR GROWTH: BLOCKING THE PATHWAYS THAT CANCER CELLS USE TO GROW AND DIVIDE.

GIVEN ITS UNIQUE MECHANISM, DARZALEX REPRESENTS A NOVEL APPROACH TO TREATING MULTIPLE MYELOMA, PARTICULARLY FOR PATIENTS WHO HAVE RELAPSED OR BECOME RESISTANT TO OTHER THERAPIES.

THE TIMELINE OF FDA APPROVALS FOR DARZALEX

THE JOURNEY OF DARZALEX THROUGH THE FDA APPROVAL PROCESS IS MARKED BY SEVERAL KEY MILESTONES:

1. INITIAL APPROVAL (2015)

DARZALEX RECEIVED ITS FIRST FDA APPROVAL ON NOVEMBER 16, 2015. THIS INITIAL APPROVAL WAS FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST THREE PRIOR LINES OF THERAPY, INCLUDING A PROTEASOME INHIBITOR AND AN IMMUNOMODULATORY AGENT, OR WHO WERE DOUBLE-REFRACTORY TO THESE TREATMENTS.

- CLINICAL TRIALS: THE APPROVAL WAS BASED ON THE RESULTS OF A PIVOTAL CLINICAL TRIAL KNOWN AS SIRIUS, WHICH DEMONSTRATED THAT DARZALEX SHOWED SIGNIFICANT EFFICACY IN PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA. THE OVERALL RESPONSE RATE WAS APPROXIMATELY 29%, WITH A MEDIAN DURATION OF RESPONSE OF 7.4 MONTHS.

2. EXPANDED APPROVAL (2016)

ON MAY 9, 2016, THE FDA EXPANDED DARZALEX'S APPROVAL TO INCLUDE USE IN COMBINATION WITH OTHER THERAPIES:

- COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE: THE APPROVAL WAS BASED ON THE RESULTS OF THE POLLUX TRIAL, WHERE THE COMBINATION SHOWED A HIGHER OVERALL RESPONSE RATE COMPARED TO THE CONTROL GROUP RECEIVING LENALIDOMIDE AND DEXAMETHASONE ALONE.

3. ADDITIONAL INDICATIONS (2017-2021)

THE APPROVAL HISTORY OF DARZALEX CONTINUED TO GROW, REFLECTING ITS VERSATILITY AND EFFECTIVENESS IN TREATING MULTIPLE MYELOMA:

- **APPROVED IN 2017:** THE FDA APPROVED DARZALEX FOR USE IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WHO HAD RECEIVED AT LEAST ONE PRIOR THERAPY. THIS WAS BASED ON THE RESULTS FROM THE CASTOR TRIAL.
- **APPROVED IN 2018:** DARZALEX WAS AGAIN APPROVED FOR USE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO WERE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WHEN COMBINED WITH BORTEZOMIB, MELPHALAN, AND PREDNISONE, BASED ON THE ALCYONE TRIAL RESULTS.
- **APPROVED IN 2020:** THE FDA GRANTED APPROVAL FOR DARZALEX IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, SHOWCASING ITS EFFECTIVENESS ACROSS DIFFERENT THERAPEUTIC COMBINATIONS.
- **APPROVED IN 2021:** THE FDA APPROVED DARZALEX FOR SUBCUTANEOUS ADMINISTRATION, ALLOWING FOR A MORE CONVENIENT ADMINISTRATION METHOD FOR PATIENTS AND HEALTHCARE PROVIDERS.

THE IMPACT OF DARZALEX ON PATIENT OUTCOMES

THE APPROVAL OF DARZALEX HAS SIGNIFICANTLY CHANGED THE TREATMENT PARADIGM FOR MULTIPLE MYELOMA. HERE ARE SOME OF THE KEY IMPACTS:

- **IMPROVED SURVIVAL RATES:** STUDIES HAVE SHOWN THAT THE ADDITION OF DARZALEX TO EXISTING TREATMENT REGIMENS HAS LED TO IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL RATES FOR PATIENTS.
- **GREATER TREATMENT OPTIONS:** PATIENTS NOW HAVE MORE OPTIONS AVAILABLE, ENABLING PERSONALIZED TREATMENT PLANS THAT CATER TO INDIVIDUAL NEEDS AND DISEASE CHARACTERISTICS.
- **ENHANCED QUALITY OF LIFE:** WITH BETTER MANAGEMENT OF THE DISEASE, PATIENTS EXPERIENCE FEWER SYMPTOMS AND IMPROVED QUALITY OF LIFE.

FUTURE DIRECTIONS AND ONGOING RESEARCH

THE JOURNEY OF DARZALEX IS FAR FROM OVER. ONGOING RESEARCH CONTINUES TO EXPLORE ITS POTENTIAL IN OTHER INDICATIONS AND COMBINATIONS. SOME AREAS OF FOCUS INCLUDE:

- **EARLY-STAGE DISEASE:** STUDIES ARE UNDERWAY TO ASSESS THE EFFICACY OF DARZALEX IN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA AND NEWLY DIAGNOSED MULTIPLE MYELOMA.
- **COMBINATIONS WITH NOVEL AGENTS:** RESEARCHERS ARE INVESTIGATING THE POTENTIAL OF COMBINING DARZALEX WITH OTHER EMERGING THERAPIES, INCLUDING CAR T-CELL THERAPY AND BISPECIFIC T-CELL ENGAGERS.
- **LONG-TERM SAFETY AND EFFICACY:** LONGITUDINAL STUDIES ARE BEING CONDUCTED TO ASSESS THE LONG-TERM OUTCOMES AND SAFETY PROFILE OF DARZALEX IN VARIOUS PATIENT POPULATIONS.

CONCLUSION

THE **DARZALEX FDA APPROVAL HISTORY** ILLUSTRATES A REMARKABLE ADVANCEMENT IN THE TREATMENT OF MULTIPLE MYELOMA. FROM ITS INITIAL APPROVAL IN 2015 TO ITS CURRENT STATUS AS A CORNERSTONE THERAPY, DARZALEX HAS PROVIDED NEW HOPE FOR COUNTLESS PATIENTS BATTLING THIS CHALLENGING DISEASE. AS RESEARCH CONTINUES AND NEW COMBINATIONS AND INDICATIONS ARE EXPLORED, DARZALEX IS POISED TO REMAIN A VITAL PART OF THE ONCOLOGY LANDSCAPE, POTENTIALLY CHANGING THE TRAJECTORY OF TREATMENT FOR FUTURE GENERATIONS OF PATIENTS.

FREQUENTLY ASKED QUESTIONS

WHAT IS DARZALEX AND WHAT CONDITION DOES IT TREAT?

DARZALEX, OR DARATUMUMAB, IS A MONOCLONAL ANTIBODY USED TO TREAT MULTIPLE MYELOMA, A TYPE OF CANCER THAT AFFECTS PLASMA CELLS IN THE BONE MARROW.

WHEN DID THE FDA FIRST APPROVE DARZALEX?

THE FDA FIRST APPROVED DARZALEX ON NOVEMBER 16, 2015, FOR USE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAD RECEIVED AT LEAST THREE PRIOR LINES OF THERAPY.

WHAT WAS THE SIGNIFICANCE OF THE FDA'S APPROVAL OF DARZALEX?

THE APPROVAL OF DARZALEX WAS SIGNIFICANT AS IT PROVIDED A NEW TREATMENT OPTION FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, IMPROVING OUTCOMES FOR THIS DIFFICULT-TO-TREAT CONDITION.

HAS DARZALEX RECEIVED ANY ADDITIONAL FDA APPROVALS SINCE ITS INITIAL APPROVAL?

YES, DARZALEX HAS RECEIVED SEVERAL ADDITIONAL FDA APPROVALS FOR VARIOUS COMBINATIONS AND SETTINGS, INCLUDING FOR USE IN NEWLY DIAGNOSED MULTIPLE MYELOMA AND IN COMBINATION WITH OTHER THERAPIES.

WHAT ARE SOME OF THE COMBINATIONS APPROVED BY THE FDA INVOLVING DARZALEX?

THE FDA HAS APPROVED DARZALEX IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE, BORTEZOMIB AND DEXAMETHASONE, AND OTHER TREATMENT REGIMENS FOR MULTIPLE MYELOMA.

WHAT WERE THE KEY CLINICAL TRIALS THAT SUPPORTED THE FDA APPROVAL OF DARZALEX?

KEY CLINICAL TRIALS, SUCH AS THE SIRIUS TRIAL AND THE CASTOR TRIAL, PROVIDED EVIDENCE OF THE EFFICACY AND SAFETY OF DARZALEX IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA.

IS DARZALEX APPROVED FOR USE IN PATIENTS WITH OTHER CONDITIONS BESIDES MULTIPLE MYELOMA?

AS OF NOW, DARZALEX IS PRIMARILY APPROVED FOR MULTIPLE MYELOMA, BUT IT IS ALSO BEING INVESTIGATED FOR USE IN OTHER HEMATOLOGICAL MALIGNANCIES, SUCH AS AL AMYLOIDOSIS.

WHAT ARE THE COMMON SIDE EFFECTS ASSOCIATED WITH DARZALEX?

COMMON SIDE EFFECTS OF DARZALEX INCLUDE INFUSION-RELATED REACTIONS, FATIGUE, NAUSEA, AND INCREASED RISK OF INFECTIONS.

HOW HAS THE APPROVAL OF DARZALEX IMPACTED THE TREATMENT LANDSCAPE FOR MULTIPLE MYELOMA?

THE APPROVAL OF DARZALEX HAS SIGNIFICANTLY IMPACTED THE TREATMENT LANDSCAPE BY PROVIDING A NEW OPTION THAT CAN IMPROVE RESPONSE RATES AND PROLONG PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA.

WHAT IS THE FUTURE OUTLOOK FOR DARZALEX IN TERMS OF FDA APPROVALS AND RESEARCH?

THE FUTURE OUTLOOK FOR DARZALEX INCLUDES ONGOING RESEARCH AND CLINICAL TRIALS TO EXPLORE ITS EFFICACY IN EARLIER LINES OF THERAPY AND IN COMBINATION WITH OTHER NOVEL AGENTS, POTENTIALLY LEADING TO ADDITIONAL FDA APPROVALS.

[Darzalex Fda Approval History](#)

Darzalex Fda Approval History

Related Articles

- [daughter of kate](#)
- [death marches in the holocaust commonlit answer key](#)
- [dbt stop skill worksheet](#)

[Back to Home](#)